Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.

Dementia and geriatric cognitive disorders - 1 Jan 2000

Almkvist O, Jelic V, Amberla K, Hellström-Lindahl E, Meurling L, Nordberg A

Abstract excerpt

A proportion of Alzheimer's disease (AD) patients treated for several months with cholinesterase (ChE) inhibitors have shown some favorable response on cognition, but the characteristics of the responders are still unclear. This study attempts to identify the characteristics of individuals with a positive behavioral response after a double-blind randomized administration of a single oral dose of tacrine (40 mg)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylcholine
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Attention

Share to Cholinesterase Inhibitors

Share to Cross-Over Studies

Share to Double-Blind Method

Share to Electroencephalography

Share to Tomography, Emission-Computed

Source

Identifiers

PMID: 11125238
DOI: 10.1159/000051232

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.PMID 11125238Read ↗

Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.Semantic proximity Read ↗

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?Semantic proximity Read ↗

Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.Semantic proximity Read ↗

Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease.Semantic proximity Read ↗

Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease.Semantic proximity Read ↗

Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-world DataSemantic proximity Read ↗

Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.Semantic proximity Read ↗

Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.Semantic proximity Read ↗

Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.Semantic proximity Read ↗

CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.Semantic proximity Read ↗

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease.Semantic proximity Read ↗

Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.